Morning! Today, we see that the FDA is extending its review period for multiple myeloma drug Blenrep. We also see more layoffs at a gene-editing company, and hear Alnylam’s CEO advocate for a new policy when it comes to Medicare price negotiations.The need-to-know this morningRoche reported second-quarter earnings. Rocket Pharmaceuticals announced a restructuring that will […]
